ORILISSA 150 MG
ELAGOLIX (ELAGOLIX SODIUM) : 150 MG · DIN 02481332 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is ORILISSA?
ORILISSA 150 MG contains ELAGOLIX (ELAGOLIX SODIUM) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02481332, held by ABBVIE CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ORILISSA used for?
Treatment of moderate to severe pain associated with endometriosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02481332 |
|---|---|
| Brand name | ORILISSA |
| Generic / active ingredient | ELAGOLIX (ELAGOLIX SODIUM) : 150 MG |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | H01CC03 ELAGOLIX |
| AHFS class | 68:18.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Oct-2018 |
| Original market date | 2018-10-30 00:00:00 |
How is it administered?
150 mg once daily or 200 mg twice daily orally at the same time each day, with or without food. Use lowest effective dose. Limit 200 mg dose to 6 months due to BMD loss.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), though typically 15-30°C for such products.
How is it supplied?
150 mg: Weekly blisters of 7 tablets (cartons of 28). 200 mg: Weekly blisters of 14 tablets (cartons of 56).
Contraindications
Hypersensitivity; pregnancy or suspected pregnancy; undiagnosed vaginal bleeding; known osteoporosis; severe hepatic impairment (Child-Pugh C); concomitant use of strong OATP1B1 inhibitors.
Warnings and precautions
Dose-dependent decrease in bone mineral density (BMD); hepatic transaminase elevations; suicidal ideation, behavior, and exacerbation of mood disorders; changes in menstrual bleeding patterns.
What can be used instead?
Other Canadian products sharing ATC code H01CC03 ELAGOLIX. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ORILISSA | 200 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02481340 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.